A Novo Nordisk-led study comparing CagriSema, its GLP-1 drug candidate for obesity, found that Eli Lilly’s Zepbound resulted in greater weight loss.
The open-label, head-to-head trial analyzed the average weight loss among adults who received weekly injections of either CagriSema or Zepbound. After 84 weeks, the CagriSema group achieved a 20.2% reduction in weight, compared to the 23.6% weight loss with Zepbound.
Novo Nordisk announced the phase 3 trial results Feb. 23. The trial included 809 adults with obesity and at least one comorbidity, according to the Denmark-based drugmaker.
This trial is part of a multi-part clinical study on CagriSema including about 4,600 adults with obesity or overweight.
In December, Novo Nordisk submitted CagriSema to the FDA for approval, and the drugmaker said a decision is expected by late 2026.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.